0
0
NEW DELHI — In a significant regulatory shift for rare immunological conditions, India’s top drug regulator, the Central Drugs Standard Control Organization (CDSCO), has officially approved AstraZeneca Pharma India’s injectable biologic Fasenra (benralizumab) for an expanded indication. Granted on July 15, 2026, the approval clears the targeted monoclonal antibody to treat hypereosinophilic syndrome (HES) in adult and adolescent patients aged 12 years and older who do not have an identifiable non-hematologic secondary cause.
The regulatory milestone introduces a highly specific, precision-medicine therapeutic option to the Indian market, expanding the use of a biologic that was previously restricted to treating severe eosinophilic asthma. The decision marks a critical advancement for patients battling HES, a rare, heterogeneous group of disorders characterized by the body’s dangerous overproduction of eosinophils—a specific type of white blood cell involved in allergic reactions and immune defense.
The Biological Impact: What the Approval Means for Patients
In a healthy immune system, eosinophils act as a defense mechanism against parasitic infections and assist in regulating allergic responses. However, in patients diagnosed with hypereosinophilic syndrome, these cells multiply uncontrollably to persistently elevated, toxic levels. Over time, these excess white blood cells infiltrate healthy body tissues, releasing destructive proteins that lead to debilitating inflammation and tissue scarring (fibrosis). If left untreated, the chronic overproduction can lead to irreversible organ failure, primarily threatening the heart, lungs, skin, and nervous system.
Fasenra addresses this mechanism through precision biology. As an interleukin-5 receptor alpha-directed cytolytic monoclonal antibody, it binds directly to the IL-5 receptor alpha subunit found on the surface of eosinophils. By doing so, it alerts the body’s natural killer cells to target and rapidly eliminate the excess eosinophils through programmed cell death (apoptosis). The CDSCO’s authorization covers the import, sale, and distribution of a 30 mg/ml solution in a pre-filled syringe, offering a targeted tool for Indian specialists managing these volatile immune responses.
Clinical Evidence Behind Benralizumab
The CDSCO’s regulatory decision relies heavily on robust data from the phase 3 NATRON clinical trial, published in Nature Medicine. The international, randomized, placebo-controlled study evaluated the efficacy and safety of benralizumab in 133 patients presenting with FIP1L1::PDGFRA-negative HES. The trial enrolled participants ranging from 14 to 87 years old (with a median age of 51 years), tracking how effectively the biological intervention delayed disease complications.
The primary endpoint results demonstrated clear therapeutic efficacy:
-
65% Risk Reduction: Patients treated with benralizumab experienced a substantial reduction in the risk of their first clinical HES flare compared to the placebo cohort, yielding a highly favorable hazard ratio of 0.35 (95% CI: 0.18–0.69; P=0.0024).
-
Safety Profile: Adverse events occurred at similar rates between the two groups, reported in 64.2% of the benralizumab-treated arm and 66.7% of the placebo group. The most common side effects included headaches, localized hypersensitivity reactions, and mild, influenza-like illness.
This late-stage research is reinforced by several smaller, longer-term longitudinal analyses. A June 2025 study published in the Journal of Allergy and Clinical Immunology: In Practice followed 20 patients with PDGFRA-negative HES over an extended follow-up window. The researchers noted that eosinophil counts remained successfully suppressed, safety was sustained, and many patients successfully achieved a “steroid-sparing effect”—meaning they were able to taper down their baseline reliance on toxic, high-dose oral corticosteroids. Similarly, a December 2024 real-world clinical series published in EJHaem observed 15 patients with severe, treatment-resistant HES, reporting stabilized eosinophil control and no serious unanticipated adverse events.
Expert Insights: Transitioning from Broad Suppression to Precision Therapy
Independent specialists emphasize that targeted biologics represent a paradigm shift away from traditional, broad-spectrum immunosuppression. Historically, clinicians have relied on heavy doses of oral corticosteroids or chemotherapy agents like hydroxyurea to force down immune cell counts. While often effective at stopping short-term flares, chronic steroid use carries a severe burden of adverse effects, including metabolic shifts, severe bone density loss, and heightened susceptibility to opportunistic infections.
“The phase 3 data are undeniably encouraging for a carefully defined cohort of HES patients,” notes an independent immunologist not involved in the AstraZeneca trials. “However, HES is a highly variable, complex spectrum of diseases. A patient’s optimal treatment strategy will always depend strictly on their specific genetic subtype, the degree of organ involvement, and how they have responded to existing foundational therapies. This is a specialized tool, not a sweeping cure-all.”
For the public, medical experts stress the importance of understanding boundaries: this drug is not a routine therapeutic for standard seasonal allergies, high eosinophil counts from standard asthma, or unclassified skin rashes. It is a high-tier prescription biologic reserved exclusively for confirmed cases of rare hypereosinophilic syndrome. Diagnosing and managing the condition requires direct supervision from specialized hematologists, allergists, or immunologists equipped to evaluate rare immunological profiles.
Public Health Implications and Practical Limitations in India
From a broader public health standpoint, the expanded approval reflects a growing momentum within India’s regulatory architecture to accommodate precision medicine and rare disease therapeutics. In India, rare disorders frequently escape early detection. Because HES symptoms mimic common conditions like severe eczema, standard asthma, or persistent parasitic infections, patients face extensive diagnostic delays, often presenting to tertiary hospitals only after irreversible tissue or cardiac damage has already occurred. By broadening the formal treatment toolkit, the CDSCO provides a vital lifeline for individuals who fail standard first-line steroid protocols.
Despite the regulatory victory, several practical hurdles remain before the drug translates into widespread clinical impact across India:
-
The Diagnostic Gap: Identifying eligible patients requires highly sophisticated laboratory diagnostics to rule out secondary causes and confirm specific negative genetic markers (such as FIP1L1::PDGFRA). Access to these advanced hematological panels remains concentrated primarily in major urban medical centers.
-
Economic Constraints: Monoclonal antibodies are notoriously expensive to manufacture, import, and distribute. For rare diseases, a massive economic gap often separates regulatory authorization from real-world patient affordability, particularly in healthcare landscapes driven largely by out-of-pocket spending.
-
Population Specificity: The clinical data validating this approval are built on specific clinical parameters—principally adolescents and adults with PDGFRA-negative variants of the disease. The findings cannot be generalized to all variants of eosinophilic or allergic disease.
Ultimately, the CDSCO’s approval represents an essential regulatory and scientific milestone. Supported by a expanding foundation of rigorous, peer-reviewed clinical data, Fasenra provides a powerful, mechanistic approach to stopping progressive organ damage in its tracks—offering a highly anticipated option for those navigating the complexities of a rare immune diagnosis.
References
https://medicaldialogues.in/news/industry/pharma/cdsco-approves-astrazenecas-fasenra-for-hypereosinophilic-syndrome-in-india-175301
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
